Esperion Therapeutis.Inc. buy StockNews.com
Summary
This prediction is currently active. With a performance of 51.90% the BUY prediction by StockNews_com is a big success. This prediction currently runs until 17.08.26. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | 18.380% | 18.380% |
iShares Core DAX® | 2.850% | 3.312% |
iShares Nasdaq 100 | 1.612% | 5.652% |
iShares Nikkei 225® | 6.401% | 11.958% |
iShares S&P 500 | 1.346% | 4.130% |
Comments by StockNews_com for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Stopped prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
05.10.24
05.10.25
06.10.25